Not intended for UK Media Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke PreventionOCEANIC-STROKE demonstrates superiority ...

The European Commission (EC) has approved Eylea 8 mg with extended treatment intervals of up to 6 months in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) / ...

Committee for Medicinal Products for Human Use (CHMP) opinion is based on the findings from the pivotal clinical trials PULSAR in neovascular (wet) age-related macular degeneration (nAMD) and PHOTON ...

Recommendation by Committee for Medicinal Products for Human Use (CHMP) based on positive results from PULSAR clinical trial in neovascular (wet) age-related macular degeneration (nAMD) and PHOTON ...

Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with ...

For people living with type 1 diabetes (T1DM), kidney health is an important part of lifelong care. Chronic kidney disease, or CKD, can develop gradually and may progress for years before symptoms ...

Kent Kalcevic’s story shows how a fifth-generation farmer responds to dry conditions by focusing on soil health, technology and the future of agriculture. His family has been operating a farm east of ...

Nina’s story highlights the importance of listening to your body and taking warning signs seriously. In a personal video, she shares why she sought medical help and how this moment shaped her ...

Group sales rise 4.1 percent (Fx & portfolio adj.) to 13.405 billion euros, negative currency effect of 886 million euros / EBITDA before special items increases 9.0 percent to 4.453 billion euros, ...

Collaboration with G+FLAS to develop new tomato varieties addresses Vitamin D deficiency affecting a billion people worldwide / Bayer also obtains a commercial product license from Pairwise for genome ...

First targeted therapy approved in Japan for this indication, with use across all lines of therapy, including first-line treatment / Approval is based on results from the ongoing Phase I/II SOHO-01 ...

Darolutamide is now the first and only androgen receptor inhibitor (ARi) approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ...